Managing Risks with Immune Therapies in Multiple Sclerosis

Moritz Förster, Patrick Küry, Orhan Aktas, Clemens Warnke, Joachim Havla, Reinhard Hohlfeld, Jan Mares, Hans-Peter Hartung () and David Kremer ()
Additional contact information
Moritz Förster: Heinrich-Heine-University
Patrick Küry: Heinrich-Heine-University
Orhan Aktas: Heinrich-Heine-University
Clemens Warnke: University Hospital Cologne
Joachim Havla: Ludwig-Maximilian-Universität München
Reinhard Hohlfeld: Ludwig-Maximilian-Universität München
Jan Mares: University Hospital and Faculty of Medicine and Dentistry, Palacky University
Hans-Peter Hartung: Heinrich-Heine-University
David Kremer: Heinrich-Heine-University

Drug Safety, 2019, vol. 42, issue 5, No 6, 633-647

Abstract: Abstract Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have all shown positive effects on clinical endpoints such as relapse rate and disease progression and are a heterogeneous group of therapeutics comprising recombinant pegylated and non-pegylated interferon-β variants, peptide combinations, monoclonal antibodies, and small molecules. However, they have relevant side effect profiles, which necessitate thorough monitoring and straightforward patient education. In individual cases, side effects can be severe and potentially life-threatening, which is why knowledge about (neurological and non-neurological) adverse drug reactions is essential for prescribing neurologists as well as general practitioners. This paper aims to provide an overview of currently available MS therapies, their modes of action and safety profiles, and the necessary therapy monitoring.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-018-0782-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-018-0782-8

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-018-0782-8

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().